ImmuCell Corporation (ICCC)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
ImmuCell Q2 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
ImmuCell: First Defense With Better Execution
ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing yields and redirected Re-Tain assets towards First Defense's production capacity. My main concern with ICCC is that it's heavily reliant on two main distributors, as well as concentrated on First Defense as its main product.
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
ImmuCell Q1 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve
ICCC's 2025 sales rise 4.3% y/y, with the gross margin expanding sharply, helping narrow its annual net loss despite asset write-downs and strategic shifts.
ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript
ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth
ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.
